Cyclohexylphenols
Medchemexpress LLC JW67 | 442644-28-2 | 98.15% | 394.38 | 50 MG
JW67 is a Wnt Signaling Inhibitor with an IC50 of 1.17 μM. It impacts the multiprotein complex of β-catenin/GSK-3β/AXIN/APC/CK1, leading to a rapid reduction in active β-catenin and downregulation of Wnt target genes. It also inhibits colorectal cancer cell growth.
- Inhibits canonical Wnt signaling
- Reduces active β-catenin
- Downregulates Wnt target genes
- Inhibits colorectal cancer cell growth
- Increases AXIN2 concentration
- Affects Wnt target gene expression
- Reduces cell growth in colon cancer cell lines
Medchemexpress LLC Trispiro[3H-indole-3,2'-dioxane-5',5''-dioxane-2'',3'''-[3H]indole]-2,2'''-dione | 442644-28-2 | MFCD03036757 | 98.15% | 394.38 | 10 MG
JW67 inhibits canonical Wnt signaling with an IC50 of 1.17 μM. It affects the multiprotein complex of β-catenin/GSK-3β/AXIN/APC/CK1, leading to a rapid reduction in active β-catenin and downregulation of Wnt target genes. This compound also inhibits colorectal cancer cell growth and reduces cell viability in SW480 cells.
- Inhibits canonical Wnt signaling with an IC50 of 1.17 μM
- Reduces active β-catenin and downregulates Wnt target genes
- Inhibits colorectal cancer cell growth
- Increases AXIN2 concentration and decreases active β-catenin in vitro
- Reduces colon cancer cell growth in vitro
- Shows concentration-dependent reduction in proliferation with a GI50 value of 7.8 μM
Medchemexpress LLC ML351 | 847163-28-4 | 99.2% | 249.27 | 10 MG
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. It demonstrates excellent selectivity (>250-fold) over related isozymes such as 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. ML351 has been shown to prevent dysglycemia and reduce β-cell oxidative stress in a nonobese diabetic mouse model of T1D.
- Potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM.
- Exhibits excellent selectivity (>250-fold) against related isozymes, including 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2.
- Prevents dysglycemia and reduces β-cell oxidative stress in a nonobese diabetic mouse model of T1D.
- Protects against diabetes development in an STZ β-cell injury model.
- Leads to improved glycemic control and significantly reduced insulitis in NOD mice.